Chad E Groer
Overview
Explore the profile of Chad E Groer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
394
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gong H, Griffin J, Groer C, Wu X, Li M, Abdelaziz M, et al.
Drug Deliv Transl Res
. 2025 Jan;
PMID: 39878856
PD-L1/PD-1 checkpoint inhibitors (CPIs) are mainstream agents for cancer immunotherapy, but the prognosis is unsatisfactory in solid tumor patients lacking preexisting T-cell reactivity. Adjunct therapy strategies including the intratumoral administration...
2.
Gong H, Griffin J, Groer C, Wu S, Downes G, Markum G, et al.
Mol Pharm
. 2024 Nov;
21(12):6323-6338.
PMID: 39484963
Unmethylated cytosine-guanine oligodeoxynucleotides (CpG ODNs) have a storied history as agonists for Toll-like receptor 9 (TLR9). CpG ODNs have shown promising antitumor effects in preclinical studies by inducing potent proinflammatory...
3.
Chakravarti A, Groer C, Gong H, Yudistyra V, Forrest M, Berkland C
Mol Pharm
. 2023 Feb;
20(4):1975-1989.
PMID: 36825806
Next-generation cancer immunotherapies may utilize immunostimulants to selectively activate the host immune system against tumor cells. Checkpoint inhibitors (CPIs) like anti-PD1/PDL-1 that inhibit immunosuppression have shown unprecedented success but are...
4.
Pressnall M, Huang A, Groer C, Huayamares S, Forrest M, Berkland C
Int J Pharm
. 2021 Jun;
605:120812.
PMID: 34144136
Cancer immunotherapy aims to stimulate immune cells to recognize and attack tumor tissue. The immunostimulatory polyanions polyI:C and CpG induce potent pro-inflammatory immune responses as TLR3 and TLR9 agonists, respectively....
5.
Huayamares S, Song J, Huang A, Crowl S, Groer C, Forrest M, et al.
Macromol Biosci
. 2020 Sep;
20(12):e2000251.
PMID: 32924274
Designing an in vitro model of the tumor extracellular microenvironment to screen intratumoral drugs is an active challenge. As recent clinical successes of human intratumoral therapies stimulate research on intratumoral...
6.
Senadheera S, Zhang T, Groer C, Forrest M
Eur J Med Chem
. 2017 May;
136:452-456.
PMID: 28525843
A new pH-activated polymer chelate of cisplatin was synthesized using a scalable and green aqueous technique. Synthesis of the chelate was based on formation of a 6-member ring of platinum(II)...
7.
Crowley R, Riley A, Sherwood A, Groer C, Shivaperumal N, Biscaia M, et al.
J Med Chem
. 2016 Dec;
59(24):11027-11038.
PMID: 27958743
Opioids are widely used to treat millions suffering from pain, but their analgesic utility is limited due to associated side effects. Herein we report the development and evaluation of a...
8.
Riley A, Groer C, Young D, Ewald A, Kivell B, Prisinzano T
J Med Chem
. 2014 Nov;
57(24):10464-75.
PMID: 25426797
The neoclerodane diterpene salvinorin A, found in the leaves of Salvia divinorum, is a potent κ-opioid receptor agonist, making it an attractive scaffold for development into a treatment for substance...
9.
Vasiljevik T, Groer C, Lehner K, Navarro H, Prisinzano T
J Nat Prod
. 2014 Jul;
77(8):1817-24.
PMID: 25075762
The success rate for central nervous system (CNS) drug candidates in the clinic is relatively low compared to the industry average across other therapeutic areas. Penetration through the blood-brain barrier...
10.
Schmid C, Streicher J, Groer C, Munro T, Zhou L, Bohn L
J Biol Chem
. 2013 Jun;
288(31):22387-98.
PMID: 23775075
There is considerable evidence to suggest that drug actions at the κ-opioid receptor (KOR) may represent a means to control pain perception and modulate reward thresholds. As a G protein-coupled...